Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)
Outcome of Board Meeting held on July 29, 2026 along with Unaudited (Standalone) Financial Results for the quarter June 30, 2026
Q1FY27 results:
Standalone:
Revenue 822m +28% y-y (642m)
EBITDA margin not explicitly stated
PAT 132m +49% y-y (89m)
- Exceptional item of 21m INR in FY26 related to labor code changes
- Employee stock options granted and shares allotted during quarter
- Buyback approved for up to 1.6m shares at 250 INR/share
- Acquisition agreement signed for 85% stake in Aequitas Healthcare for 208m INR
- Board approved final dividend of 4 INR/share for FY26
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 JAGSNPHARM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add JAGSNPHARM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Jagsonpal Pharmaceuticals Limited
Important.
The summary above is generated automatically from Jagsonpal Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.